Satellos Bioscience Inc. (TSX:MSCL)

Satellos Bioscience Cash Flow Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-28.1	-15.89	-11.32	-15.51	-1.58
Depreciation & Amortization	0.02	0.01	0.34	0.17	0
Asset Writedown & Restructuring Costs	3.92	-	2.89	-	-
Loss (Gain) From Sale of Investments	0.04	-	-0.04	-	-
Stock-Based Compensation	2.11	2.17	1.44	0.97	0.09
Other Operating Activities	-1.95	1.76	0.07	9.82	0.01
Change in Accounts Receivable	-	-	-	0.04	-0.03
Change in Accounts Payable	1.38	0.79	0.73	-0.39	-0.44
Change in Other Net Operating Assets	-2.4	-0.43	0.27	-0.14	0.29
Operating Cash Flow	-24.98	-11.59	-5.64	-5.03	-1.66
Capital Expenditures	-0.01	-0.02	-0	-0.01	-
Cash Acquisitions	-	-	-	1.75	-
Investment in Securities	6.34	-17.52	-	-	-
Investing Cash Flow	6.34	-17.54	-0	1.74	-
Short-Term Debt Issued	-	2.38	-	-	-
Long-Term Debt Issued	-	-	-	0.19	1.09
Total Debt Issued	-	2.38	-	0.19	1.09
Short-Term Debt Repaid	-	-2.62	-	-	-
Total Debt Repaid	-	-2.62	-	-	-
Net Debt Issued (Repaid)	-	-0.24	-	0.19	1.09
Issuance of Common Stock	43.64	35.16	2	7.26	0.89
Other Financing Activities	9.85	15.51	0.78	-	-
Financing Cash Flow	53.49	50.43	2.78	7.45	1.98
Foreign Exchange Rate Adjustments	0.74	-1.16	-0.08	-0	-
Net Cash Flow	35.59	20.14	-2.95	4.15	0.32
Free Cash Flow	-24.98	-11.6	-5.65	-5.04	-1.66
Free Cash Flow Per Share	-0.22	-0.13	-0.16	-0.21	-0.09
Levered Free Cash Flow	-16.15	-7.25	-2.5	-0.16	-1.1
Unlevered Free Cash Flow	-16.15	-7.14	-2.5	-0.13	-1.1
Change in Net Working Capital	0.89	-0.37	-0.99	-1.72	0.18

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.